Remedy is now building the next growth leap of its strategy with the 5 major game projects under development. This will be reflected in rising costs between 2022 and 2023, but enable significant earnings growth particularly in 2025-2026, driven by increasing royalty income. In terms of long-term growth potential, we see the share's risk/return ratio as attractive, but with our lowered forecasts, this will take longer to materialize than previously expected. Thus, in the short term, the attractiveness of the stock has weakened compared to our previous estimates.
Show your love by gifting this content to a fellow investor. As a Premium subscriber you can gift Premium-content to a free-user friend. Gift link: